Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia.
Xie Z, Zhang M, Song Q, Cheng L, Zhang X, Song G, Sun X, Gu M, Zhou C, Zhang Y, Zhu K, Yin J, Chen X, Li J, Nan F.
Xie Z, et al.
Acta Pharm Sin B. 2023 Feb;13(2):739-753. doi: 10.1016/j.apsb.2022.06.011. Epub 2022 Jun 18.
Acta Pharm Sin B. 2023.
PMID: 36873173
Free PMC article.